Towards the end of 2016, the ownership of APN311 (also known as dinutuximab beta) transferred from Apeiron Biologics to EUSA Pharma. As a result of this, EUSA Pharma has regretfully had to inform NICE that it is unable to provide an evidence submission for this appraisal in line with the scheduled timelines. Therefore, we have had to cancel the scheduled committee meetings.
Please be assured that EUSA Pharma and NICE are actively engaging in discussions to establish updated timelines for the company submission, so that we can re-schedule this appraisal accordingly. We will provide a further update as soon as we have more details.